Y-Intercept (HK)’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Y-Intercept (HK)’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-18,463	Closed	-$98.8K	–	2028
2024 Q1	$98.8K	Buy	18,463 +7,951	+76%	+$55K	0.01%	1282
2023 Q4	$81.9K	Buy	+10,512	New	+$36K	0.01%	1126
2022 Q3	–	Sell	-1,013	Closed	-$10K	–	1336
2022 Q2	$10K	Buy	+1,013	New	+$9.48K	﹤0.01%	815

Other funds holding SYRS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Y-Intercept (HK)'s SYRS Position: Q2 2024 in Review

Y-Intercept (HK) sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2024, closing a stake of 18,463 shares — an estimated $98.8K sold.

Y-Intercept (HK) first reported a position in SYRS in Q2 2022 and held it in 3 quarters. The position peaked at $98.8K in Q1 2024. 70 funds tracked by Wall St. Rank hold SYRS as of Q2 2024.

Y-Intercept (HK) reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Y-Intercept (HK) sold 18,463 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $98.8K.
Y-Intercept (HK) first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2022 and held it in 3 quarters.
Y-Intercept (HK)'s Syros Pharmaceuticals, Inc. Common Stock position peaked at $98.8K in Q1 2024.
70 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on Y-Intercept (HK)'s 13F filing for Q2 2024, filed 14 Aug 2024.